Stryker Corporation (NYSE:SYK) insider David Floyd sold 19,305 shares of the company’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total value of $2,790,730.80. The transaction was disclosed in a document filed with the SEC, which is available through this link.
David Floyd also recently made the following trade(s):
- On Monday, June 5th, David Floyd sold 7,381 shares of Stryker Corporation stock. The shares were sold at an average price of $144.70, for a total value of $1,068,030.70.
Shares of Stryker Corporation (NYSE SYK) traded down 0.42% on Monday, reaching $144.79. The company had a trading volume of 340,258 shares. The firm has a market cap of $54.12 billion, a P/E ratio of 32.54 and a beta of 0.79. The company has a 50-day moving average price of $140.23 and a 200-day moving average price of $130.49. Stryker Corporation has a one year low of $106.48 and a one year high of $145.99.
Stryker Corporation (NYSE:SYK) last released its earnings results on Tuesday, April 25th. The medical technology company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.43 by $0.05. The company had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $2.90 billion. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.33%. The firm’s quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.24 earnings per share. On average, analysts expect that Stryker Corporation will post $6.43 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, July 31st. Stockholders of record on Friday, June 30th will be given a dividend of $0.425 per share. The ex-dividend date of this dividend is Wednesday, June 28th. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.17%. Stryker Corporation’s payout ratio is currently 38.20%.
TRADEMARK VIOLATION WARNING: “Stryker Corporation (SYK) Insider David Floyd Sells 19,305 Shares” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2722874/stryker-corporation-syk-insider-david-floyd-sells-19305-shares.html.
Large investors have recently added to or reduced their stakes in the company. Bollard Group LLC boosted its stake in shares of Stryker Corporation by 0.4% in the first quarter. Bollard Group LLC now owns 829 shares of the medical technology company’s stock worth $109,000 after buying an additional 3 shares during the period. Baystate Wealth Management LLC boosted its stake in shares of Stryker Corporation by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock worth $139,000 after buying an additional 22 shares during the period. James Investment Research Inc. bought a new stake in shares of Stryker Corporation during the second quarter worth approximately $155,000. Guardian Life Insurance Co. of America boosted its stake in shares of Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock worth $158,000 after buying an additional 9 shares during the period. Finally, Assetmark Inc. boosted its stake in shares of Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock worth $168,000 after buying an additional 4 shares during the period. Institutional investors own 74.25% of the company’s stock.
Several equities research analysts recently issued reports on SYK shares. Oppenheimer Holdings, Inc. set a $135.00 price target on Stryker Corporation and gave the company a “hold” rating in a research report on Saturday, April 8th. BMO Capital Markets reissued a “hold” rating and set a $125.00 price target on shares of Stryker Corporation in a research report on Tuesday, April 11th. Jefferies Group LLC reissued a “hold” rating and set a $132.00 price target on shares of Stryker Corporation in a research report on Thursday, April 13th. Piper Jaffray Companies reissued an “overweight” rating and set a $148.00 price target on shares of Stryker Corporation in a research report on Monday, April 17th. Finally, Needham & Company LLC reissued a “sell” rating on shares of Stryker Corporation in a research report on Wednesday, April 26th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the stock. Stryker Corporation currently has a consensus rating of “Hold” and an average target price of $138.36.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.